Stability Testing for Drug Substances and Drug Products

11 – 12 November 2015, Berlin, Germany

Highlights:

- Update on current ICH and CHMP Guidelines for stability
- Stability testing from early development to product launch
- Stability Testing strategies for Drug Products
- Essential hints for writing the stability part in the CTD
- Stability Studies after approval (EU/US)
- Evaluation of stability results – Statistical Considerations
Objectives

This event is intended to provide information on different aspects of stability testing. The conference will be opened by an overview of stability testing with a special focus on important changes in current revisions of ICH Guidelines. In the subsequent presentations, practical aspects of stability testing for drug substances and throughout drug development are discussed.

The second day commences with a lecture on stability testing for Drug Products and a risk based approach for stability testing covering different climatic zones. In the following talks special consideration is given to the various aspects of post-marketing stability testing procedures. The specific challenges of data evaluation and the structure of the Common Technical Document (CTD) will then be addressed.

Background

Analytical methods that were not “stability-indicating” are frequently cited in FDA 483s and Warning Letters. This conference will thus address how to set impurity limits for related substances and degradation products based on method capability and stability results. Furthermore, genotoxic impurities and strategies for their control will be presented and QbD (Quality by Design) will also be discussed.

The analytical result, which will be compared to the specification, is affected by the variability of the measurement itself and depends also on the sampling process and on the variability of the manufacturing process of the tested product itself. This makes statistical considerations essential and consideration of the associated measurement uncertainties vital when setting or complying with specifications. Finally, specifications for the API (drug substance), excipient(s) and the drug product are part of the quality section of the marketing authorisation application which has to be submitted to the competent authority.

Target Audience

This conference is of particular interest to specialists from QA, QC and Regulatory Affairs departments of the API and pharmaceutical industry and CROs as well as to members of the EU inspectorates and authorities. Participants have the opportunity to exchange their experiences they gained with the different aspects of ‘specifications’ with the experts from the API and pharmaceutical industry as well as with members of competent authorities.

Moderator

DR THOMAS FÜRST, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany

Programme

Current ICH and CHMP Guidelines for Stability Testing
- Overview of Stability Guidelines
- Concepts of Stability testing
- Retest period and Shelf-life
- Post-marketing Stability Studies
- Future Activities

Stability Testing throughout Drug Development
- Must the development stability programme meet ICH Q1A?
- Stability testing from early development to product launch
- Clinical stability for comparators
- Site specific stability

Stability Testing for Drug Substances
- Stability protocols
- Stress testing
- Photostability testing
- Documentation
Programme

Stability Testing for Drug Products
- Strategy of Stability Testing
- Performance of new Drug Products
- Related Finished Products with existing substances
- Follow-up Stability Testing

Submitting Stability Data – The CTD-Structure
- Drug Substance Stability
- Drug Product Stability
- Storage Recommendations/Labelling
- Essential hints for writing the stability part in the CTD

Evaluation of Stability Results – Statistical Considerations
- Sample number and replication
- Trend analysis
- Outliers
- Pooling of batch data
- Shelf life prediction

Post-marketing Stability Testing
- Stability Studies after Approval (EU/US)
- Changes with Impact on Stability
- Examples

Speakers

Dr Thomas Fürst, Boehringer-Ingelheim Pharma KG, Biberach, Germany
Dr Fürst joined Schering in 1987 working in a production facility for oral dosage forms. Later he joined the analytical development department. His responsibilities were method development and validation of analytical methods. In 2006 Dr. Fürst was appointed head of the Pharmaceutical Development Services group of Bayer Schering Pharma AG in Berlin. In Aug 2007 Dr. Fürst joined Boehringer Ingelheim as a CMC expert. At present he is a project leader in the development department for consumer healthcare products at Boehringer Ingelheim.

Dr Wolfgang Grimm, Biberach, Germany
Dr Grimm was responsible for the analytical development and stability testing at Boehringer Ingelheim Pharma KG in Biberach. He wrote 35 papers and 4 books on Stability Testing and Analytical Development. He has been invited for lectures and workshops in Europe, USA, Japan, Brazil, South Africa, Thailand, Taiwan and Turkey. He has participated in the working party of the ICH Stability Guideline as a representative of the European Pharmaceutical Industry. He has been invited by the FDA as an advisor for the climatic zone concept.

Dr Hiltrud Horn, Horn Pharmaceutical Consulting, Germany
Dr Hiltrud Horn is managing director of HORN PHARMACEUTICAL CONSULTING. From 1990 to 1997, she was employed by Hoffmann-La Roche in Quality Control/Quality Assurance. From 1997 to 1999, she dealt with medical writing in the ‘International Drug Regulatory Affairs and Project Management’ department of the same company. In 1999, she joined Knoll AG as head of the departments ‘Regulatory Compliance and CMC Documentation’ and ‘Dossier Production and Compliance’ for international drug registration. In 2002, she started at Cap Gemini Ernst & Young, where she was the responsible consultant for questions concerning biotechnology and life sciences.

Dr Jordi Ruiz-Combalia, Audit GMP, Spain
Dr. Ruiz-Combalia has 30 years experience in the Active Pharmaceutical Ingredient Industry, where he has had different responsibilities. In his current position he has been working as R&D Director. Since 1992, he is a member of the Organic Chemistry Expert Group of the Real Farmacopea Española. Since 1994, he is member of the Groups of Experts of the European Pharmacopoeia, currently chairman of Group 11S and collaborates with the APIC (Active Pharmaceutical Ingredients Committee) in the GMP Working Group.

Dr Wilhelm Schlumbohm, Berlin, Germany
Dr Schlumbohm worked more than 20 years with German drug licensing authorities in the field of assessment of the CMC parts of new drug applications. He works as expert for the Certification Procedure of the European Pharmacopoeia.

Dr Thomas Uhlich, Bayer Pharma, Germany
Dr Uhlich is a chemist and has been working in Global Drug Discovery at Bayer Pharma AG for several years. He is heading a laboratory which is specialized in the development and validation of analytical methods as well as the stability testing of pharmaceuticals in clinical development.
E-Mail: info@concept-heidelberg.de
Organisation and Contact
ECA has entrusted Concept Heidelberg with the organisation of this event.
CONCEPT HEIDELBERG
P.O. Box 10 17 64
69007 Heidelberg, Germany
Phone: +49 (0) 62 21/84 44-0
Fax: +49 (0) 62 21/84 44 34
info@concept-heidelberg.de

The responsible operations director
Dr. Gerhard Becker,
phone: +49(0)62 21/84 44 65,
becker@concept-heidelberg.de
will help you with any technical questions as regards content.

Ms. Nicole Bach
phone: +49 (0) 62 21 / 84 44 22,
bach@concept-heidelberg.de,
the responsible organisation manager,
is happy to help you with any questions concerning reservation, hotel, etc.

General terms and conditions
If you cannot attend the conference you have two options:
1. We are happy to welcome a substitute colleague at any time.
2. If you have to cancel entirely we must charge the following processing fees: Cancellation until 2 weeks prior to the conference 10 %, within 1 week prior to the conference 50 %. CONCEPT HEIDELBERG reserves the right to cancel the event without notice or to cancel an event.

Privacy Policy: By registering for this event, I accept the processing of my Personal Data. Concept Heidelberg will use my data for the processing of this order, for which I hereby declare to agree that my personal data is stored and processed. Concept Heidelberg will only send me information in relation with this order or similar ones. My personal data will not be disclosed to third parties (see also the privacy policy at http://www.gmp-compliance.org/eca_privacy.html). I note that I can ask for the modification, correction or deletion of my data at any time via the contact form on this website.

Social Event
On 11 November, you are cordially invited to a dinner. This is an excellent opportunity to share your experiences with colleagues from other companies in a relaxed atmosphere.